EUVIMEDEUVIMED entdecken
Crossref

β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam

Abdullah Tozluyurt

Current Microbiology · 2026-06 · 83 (6)

DOI: 10.1007/s00284-026-04892-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Microbiology, online erschienen am 16.04.2026. Verfasst von Abdullah Tozluyurt. Beteiligte Einrichtung: Faculty of Medicine, Department of Medical Microbiology, School of Medicine, Hacettepe University, Ankara, Turkey. abdullahtozluyurt@hacettepe.edu.tr. Hauptthemen laut MEDLINE: Cephalosporins, Azabicyclo Compounds, Pseudomonas aeruginosa, beta-Lactamases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudomonas aeruginosa remains one of the most formidable Gram-negative pathogens due to its extensive β-lactamase repertoire and rapidly evolving multidrug resistance. Cefiderocol, a novel siderophore cephalosporin, has emerged as a promising option against carbapenem-resistant isolates; however, its activity may be compromised in the presence of class A β-lactamases. Avibactam, a potent inhibitor of class A, class C, and selected class D β-lactamases, offers a rational strategy to restore cefiderocol efficacy. In this study, the in vitro activity of cefiderocol alone and in combination with avibactam was evaluated against 38 non-duplicate clinical carbapenem-resistant P. aeruginosa isolates collected at Hacettepe University. Antimicrobial susceptibility was assessed by disc diffusion, gradient test, and broth microdilution, while β-lactamase genes were identified by PCR and sequencing. The cefiderocol–avibactam combination was tested using a fixed avibactam concentration of 4 mg/L. Cefiderocol resistance was detected in 84.2% of isolates, with blaVEB, blaPER, and blaVIM being the most prevalent resistance determinants. Notably, the addition of avibactam produced a pronounced ≥ 8.5-fold mean reduction in cefiderocol minimum inhibitory concentrations among class A β-lactamase producers and restored susceptibility in 21 of 36 resistant isolates, whereas metallo-β-lactamase–producing strains showed minimal response. Overall, the cefiderocol–avibactam combination demonstrated significantly enhanced in vitro activity compared with cefiderocol alone (p < 0.00001), underscoring its potential clinical value as a rescue therapeutic option for infections caused by extended-spectrum β-lactamase–producing, carbapenem-resistant P. aeruginosa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalosporinsAzabicyclo CompoundsPseudomonas aeruginosabeta-LactamasesAnti-Bacterial AgentsCarbapenemsbeta-Lactamase InhibitorsCefiderocolMicrobial Sensitivity TestsHumansPseudomonas InfectionsDrug Resistance, Multiple, Bacterial

Substanzen

CefiderocolCephalosporinsAzabicyclo Compoundsbeta-LactamasesAnti-Bacterial AgentsavibactamCarbapenemsbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Medical Microbiology, School of Medicine, Hacettepe University, Ankara, Turkey. abdullahtozluyurt@hacettepe.edu.tr.

Zitieren

APA

Tozluyurt, A. (2026). β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam. Current Microbiology, 83(6). https://doi.org/10.1007/s00284-026-04892-4

Vancouver

Tozluyurt A. β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam. Current Microbiology. 2026;83(6). doi:10.1007/s00284-026-04892-4

BibTeX
@article{Tozluyurt2026,
  author = {Tozluyurt, Abdullah},
  title = {β-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam},
  journal = {Current Microbiology},
  year = {2026},
  volume = {83},
  number = {6},
  doi = {10.1007/s00284-026-04892-4}
}
Kostenlos starten →